Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins

Annals of the New York Academy of Sciences

Volumn 947, Issue , 2001, Pages 229-246

  Gryglewski, Ryszard J ^a   Uracz, Wojciech ^a   Swies, Józef ^a   Chlopicki, Stefan ^a   Marcinkiewicz, Ewa ^a   Lomnicka, Magdalena ^a   Madej, Józef ^a   Clowes, A ^a   Hansson, G ^a   Steinberg, D ^a   Numano, F ^a   Fuster, V ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Angiotensin converting enzyme inhibitors; Statins

Indexed keywords

ATORVASTATIN; BRADYKININ; CALCIUM; CERIVASTATIN; CORONARY VASODILATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; LACTONE; MEVINOLIN; NITRIC OXIDE; PERINDOPRIL; PERINDOPRILAT; PROSTACYCLIN; QUINAPRIL; QUINAPRILAT; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL BLOOD; BLOOD CLOT LYSIS; CATTLE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; ISOLATED HEART; LUNG CIRCULATION; NONHUMAN; PLEIOTROPY; PRENYLATION; RAT; SWINE;

ANIMALIA; BOS TAURUS; BOVINAE; CAVIA PORCELLUS; SUS SCROFA;

EID: 0035683590     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03945.x     Document Type: Conference Paper

References (31)

1. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation
2. 2 receptor activation
3. Endothelial dysfunction and inhibition of converting enzyme
4. Modification of endothelial function: New method of antihypertensive treatment
5. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
6. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF Study)
7. Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dusfunction
8. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study
9. Low-density lipoprotein effects of statins
10. Current perspectives on statins
11. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
12. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
13. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
14. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
15. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs
16. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription
17. Simvastatin improves disturbed endothelial barrier function
18. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
19. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
20. Thienopyridines: Effects on cultured endothelial cells
21. 2+ indicators with greatly improved fluorescence properties
22. Nitric oxide is a major mediator in reactive hyperaemia evoked by a brief coronary occlusion in the guinea heart
23. Unusual effects of aspirin on ticlopidine induced thrombolysis
24. Effect of ticlopidine on streptokinase-induced thrombolysis in rats
25. Streptokinase-induced changes in the structure of platelets. Ex vivo study
26. Statins and blockers of the renin-angiotensin system: Vascular protection beyond their primary mode of action
27. The history of inhibitors of angiotensin converting enzyme
28. Generation of prostacyclin by lungs in vivo and its release into the arterial circulation
29. Lungs as a generator of prostacyclin: Hypothesis on physiological significance
30. Is the lung an endocrine organ that secretes prostacyclin?
31. Le poumon producteur de prostacycline